Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S. Kim, Jean‐Yves Douillard, Vera Hirsh et al.|The Lancet|2008Cited by 1.2k
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.Joyce O’Shaughnessy, Daniel D. Von Hoff, Waun Ki Hong et al.|PubMed|2002Cited by 383
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trialAssuntina G. Sacco, Ezra E.W. Cohen, Ruifeng Chen et al.|The Lancet Oncology|2021Cited by 257
Future cancer research priorities in the USA: a Lancet Oncology CommissionElizabeth M. Jaffee, Richard Sullivan, Chi V. Dang et al.|The Lancet Oncology|2017Cited by 209